
PhaseBio Presents Data from Phase 1b/2a Trial of Pemziviptadil
MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, recently announced presentation of data from …
Read More